Stockscreener 앱 받기
5.7548
2.62%
-0.1552
전일 마감가:
$5.91
열려 있는:
$5.92
하루 거래량:
1.34M
Relative Volume:
0.16
시가총액:
$1.97B
수익:
-
순이익/손실:
$-75.80M
주가수익비율:
-16.44
EPS:
-0.35
순현금흐름:
$-68.07M
1주 성능:
-1.62%
1개월 성능:
-38.38%
6개월 성능:
+124.80%
1년 성능:
+107.76%
1일 변동 폭
$5.72
$6.00
1주일 범위
$5.60
$6.25
52주 변동 폭
$1.54
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
명칭
Nuvation Bio Inc
전화
(415) 754-3517
주소
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
NUVB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
5.755 | 2.03B | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.58 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.63 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.38 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.67 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-19 | 개시 | B. Riley Securities | Buy |
| 2025-09-30 | 개시 | Jefferies | Buy |
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-03-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-03-26 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-05-04 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-04-06 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 개시 | BMO Capital Markets | Outperform |
| 2021-03-08 | 개시 | BTIG Research | Buy |
| 2021-03-08 | 개시 | Cowen | Outperform |
| 2021-03-08 | 개시 | Jefferies | Buy |
| 2021-03-08 | 개시 | Wedbush | Outperform |
모두보기
Nuvation Bio Inc 주식(NUVB)의 최신 뉴스
Nuvation Bio Inc. (NYSE:NUVB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Nuvation Bio (NYSE:NUVB) Stock Price Down 4.2%Here's Why - MarketBeat
Nuvation Bio Inc. (NUVB) price target lowered as IBTROZI sales meet expectations - MSN
Why Nuvation Bio (NUVB) Is Down 8.2% After Expanding Global Taletrectinib Partnership With Eisai - simplywall.st
Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations - Yahoo Finance
Top 10 Oncology Stocks to Buy Now - Insider Monkey
Here’s What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) - Insider Monkey
Here's What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) - Finviz
10 Stocks Under $10 with High Potential - Insider Monkey
Aug Closing: Whats the analyst consensus on Surrozen IncLong Setup & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Is Nuvation Bio (NUVB) Pricing In Its Sharp Swings Or A Long Runway For Growth - Yahoo Finance
Signal Recap: Should I invest in KORE Group Holdings Inc before earningsJuly 2025 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal - Yahoo Finance
A Look At Nuvation Bio’s Valuation After The Eisai Taletrectinib Collaboration Agreement - Sahm
Is Nuvation Bio Inc stock undervalued right nowMarket Growth Report & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Eisai and Nuvation Bio ink licensing deal for taletrectinib - The Pharma Letter
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib - Insider Monkey
Jones Trading raises Nuvation Bio stock price target to $12 on safusidenib study - Investing.com Nigeria
Jones Trading raises Nuvation Bio stock price target to $12 on safusidenib study By Investing.com - Investing.com Australia
Q1 EPS Estimates for Nuvation Bio Boosted by HC Wainwright - MarketBeat
Wall Street Analysts Believe Nuvation Bio (NUVB) Could Rally 25.14%: Here's is How to Trade - MSN
Nuvation Bio (NUVB) Expands Global Taletrectinib Rights With Eisai Collaboration And Licensing Deal - simplywall.st
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights
Nuvation Bio stock price target lowered to $17 at H.C. Wainwright - Investing.com Nigeria
Weekly Earnings: Will Nuvation Bio Inc stock outperform value stocksJobs Report & Free Safe Capital Growth Stock Tips - moha.gov.vn
Down 24% in 4 Weeks, Here's Why Nuvation Bio (NUVB) Looks Ripe for a Turnaround - Yahoo Finance
Nuvation Bio stock rating reiterated at Market Outperform by Citizens - Investing.com Nigeria
Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens - TechStock²
Nuvation Bio and Eisai license Taletrectinib rights outside US, China and Japan for $230 M - BioSpectrum Asia
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan - Quamnet
Nuvation Bio Faces Challenges Amidst Financial and Market Turbulence - StocksToTrade
NUVB Stock Dips Amidst Market Uncertainty and Strategic Pressure - StocksToTrade
Expert Outlook: Nuvation Bio Through The Eyes Of 9 Analysts - Benzinga
NUVB Stock Surges Following Promising Expansion News - timothysykes.com
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan - BioSpace
Nuvation Bio (NYSE:NUVB) Shares Gap Down After Analyst Downgrade - MarketBeat
HC Wainwright Has Lowered Expectations for Nuvation Bio (NYSE:NUVB) Stock Price - MarketBeat
Nuvation Stocks Dip on Hookup with Japanese Firm - Baystreet.ca
Nuvation Bio (NUVB): HC Wainwright & Co. Lowers Price Target, Ma - GuruFocus
Nuvation Bio Expands Global Reach with Eisai Partnership - TipRanks
Nuvation Bio Reports Preliminary Fourth Quarter And Full Year 2025 Financial Results And Provides 2026 Outlook Ahead Of 44Th Annual J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Nuvation Bio Signs License and Collaboration Agreement With Eisai - TradingView — Track All Markets
Nuvation Bio and Eisai enter into exclusive licensing agreement for taletrectinib in Europe and additional countries outside U.S., China and Japan - marketscreener.com
Why Nuvation Bio Inc. Warrants stock gets analyst attentionWeekly Stock Recap & Fast Gain Swing Trade Alerts - Улправда
Nuvation Bio Inc (NUVB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.42%
1.57%
자본화:
|
볼륨(24시간):